Immunization Study News Today

ABRYSVO is the first and only RSV vaccine approved in the European Union for both older adults and for immunization of pregnant individuals to help protect their infants immediately from birth...

Pfizer Inc. announced that the U.S. Food and Drug Administration has approved ABRYSVO? , the company?s bivalent RSV prefusion F vaccine, for the prevention of LRTD and severe LRTD caused by RSV in...

The respiratory syncytial virus (RSV) vaccine Abrysvo is approved for use in pregnant individuals to prevent the RSV in infants up to 6 months of age.

First and only U.S. approval of a maternal vaccine to help protect infants at birth through six months of life from lower respiratory tract disease and severe LRTD due to RSV FDA’s decision is...

The US FDA's VVRBPAC has voted in favour of Pfizer’s unadjuvanted bivalent respiratory syncytial virus prefusion F vaccine candidate, RSVpreF

The positive vote is based on compelling scientific evidence presented, including Phase 3 efficacy and safety data in pregnant individuals and their infants FDA decision expected in August... | May 18, 2023

The positive vote is based on compelling scientific evidence presented, including Phase 3 efficacy and safety data in pregnant individuals and their infants FDA decision expected in August

The trial did not meet the second primary efficacy endpoint of medically attended respiratory syncytial virus-associated lower respiratory tract illness.

Three major respiratory viruses—respiratory syncytial virus, seasonal influenza, and COVID-19—are surging at once, prompting a determined scientific response.

Southern California’s Orange County Health Department this month declared a local health emergency over concerns around the rising number of pediatric cases of Respiratory Syncytial Virus (RSV). [...]